These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 16509469)

  • 1. No change in circulating osteoprotegerin levels by intravenous calcitriol therapy among dialysis patients with secondary hyperparathyroidism.
    Nishi H; Nii-Kono T; Ikeda K; Fujimori A; Fukagawa M
    Clin Nephrol; 2006 Feb; 65(2):149-50. PubMed ID: 16509469
    [No Abstract]   [Full Text] [Related]  

  • 2. Maxacalcitol therapy decreases circulating osteoprotegerin levels in dialysis patients with secondary hyperparathyroidism.
    Kazama JJ; Omori K; Takahashi N; Ito Y; Maruyama H; Narita I; Gejyo F; Iwasaki Y; Fukagawa M
    Clin Nephrol; 2005 Jul; 64(1):64-8. PubMed ID: 16047647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correspondence re: A. Lipton et al., Serum osteoprotegerin levels in healthy controls and cancer patients. Clin. Cancer Res., 8: 2306-2310, 2002.
    Dovio A; Sartori ML; Angeli A
    Clin Cancer Res; 2003 Jun; 9(6):2384-5; author reply 2386. PubMed ID: 12796409
    [No Abstract]   [Full Text] [Related]  

  • 4. ELISA methodology for detection of modified osteoprotegerin in clinical studies.
    Chen D; Sarikaya NA; Gunn H; Martin SW; Young JD
    Clin Chem; 2001 Apr; 47(4):747-9. PubMed ID: 11274028
    [No Abstract]   [Full Text] [Related]  

  • 5. Circulating osteoprotegerin is not removed through haemodialysis membrane.
    Kazama JJ; Kato H; Sato T; Shigematsu T; Fukagawa M; Iwasaki Y; Gejyo F
    Nephrol Dial Transplant; 2002 Oct; 17(10):1860-1. PubMed ID: 12271009
    [No Abstract]   [Full Text] [Related]  

  • 6. [Osteoprotegerin (OPG)].
    Takahashi N; Kimura H; Yoshida H
    Nihon Rinsho; 2005 Aug; 63 Suppl 8():818-20. PubMed ID: 16149650
    [No Abstract]   [Full Text] [Related]  

  • 7. Increased serum osteoprotegerin level in older and diabetic hemodialysis patients.
    Doi S; Yorioka N; Masaki T; Ito T; Shigemoto K; Harada S
    Ther Apher Dial; 2004 Aug; 8(4):335-9. PubMed ID: 15274686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immuno-PCR assay for homodimeric osteoprotegerin.
    Furuya D; Kaneko R; Yagihashi A; Endoh T; Yajima T; Kobayashi D; Yano K; Tsuda E; Watanabe N
    Clin Chem; 2001 Aug; 47(8):1475-7. PubMed ID: 11468243
    [No Abstract]   [Full Text] [Related]  

  • 9. [PTH and bone metabolism in chronic dialysis patients].
    Fukagawa M; Kazama J; Shigematsu T
    Rinsho Byori; 2001 Mar; 49(3):236-8. PubMed ID: 11307321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation and prognostic value of serum osteoprotegerin in multiple myeloma.
    Depil S; Mathiot C; Leleu X; Moreau AS; Faucompré JL; Hennache B; Bauters F; Bataille R; Facon T
    Br J Haematol; 2005 Jun; 129(5):706-7. PubMed ID: 15916694
    [No Abstract]   [Full Text] [Related]  

  • 11. Using the ratio of serum osteoprotegerin ligand to osteoprotegerin to evaluate renal osteodystrophy in dialysis patients.
    Grzegorzewska AE; Mlot M
    Adv Perit Dial; 2005; 21():188-93. PubMed ID: 16686316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteoprotegerin (OPG) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) levels in atherosclerosis.
    Schoppet M; Sattler AM; Schaefer JR; Hofbauer LC
    Atherosclerosis; 2006 Feb; 184(2):446-7. PubMed ID: 16325821
    [No Abstract]   [Full Text] [Related]  

  • 13. Skeleton key to vascular disease.
    Demer LL; Abedin M
    J Am Coll Cardiol; 2004 Nov; 44(10):1977-9. PubMed ID: 15542279
    [No Abstract]   [Full Text] [Related]  

  • 14. Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure.
    Kazama JJ; Shigematsu T; Yano K; Tsuda E; Miura M; Iwasaki Y; Kawaguchi Y; Gejyo F; Kurokawa K; Fukagawa M
    Am J Kidney Dis; 2002 Mar; 39(3):525-32. PubMed ID: 11877571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Paracalcitiol compared with calcitriol in treatment of secondary hyperparathyroidism in patients with hemodyalisis. Are they really different?].
    Peña-Rodriguez JC
    Rev Invest Clin; 2004; 56(1):8-10. PubMed ID: 15144035
    [No Abstract]   [Full Text] [Related]  

  • 16. Osteoprotegerin levels before and after renal transplantation.
    Sato T; Tominaga Y; Iwasaki Y; Kazama JJ; Shigematsu T; Inagaki H; Watanabe I; Katayama A; Haba T; Uchida K; Fukagawa M
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 1):S175-7. PubMed ID: 11576949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of a serum assay for quantification of abdominal aortic calcification.
    Clancy P; Oliver L; Jayalath R; Buttner P; Golledge J
    Arterioscler Thromb Vasc Biol; 2006 Nov; 26(11):2574-6. PubMed ID: 17053174
    [No Abstract]   [Full Text] [Related]  

  • 18. Plasma osteoprotegerin is associated with mortality in hemodialysis patients.
    Morena M; Terrier N; Jaussent I; Leray-Moragues H; Chalabi L; Rivory JP; Maurice F; Delcourt C; Cristol JP; Canaud B; Dupuy AM
    J Am Soc Nephrol; 2006 Jan; 17(1):262-70. PubMed ID: 16280472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients.
    Seminari E; Castagna A; Soldarini A; Galli L; Fusetti G; Dorigatti F; Hasson H; Danise A; Guffanti M; Lazzarin A; Rubinacci A
    HIV Med; 2005 May; 6(3):145-50. PubMed ID: 15876279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteoprotegerin serum levels in multiple myeloma and MGUS patients compared with age- and sex-matched healthy controls.
    Corso A; Dovio A; Rusconi C; Sartori ML; Klersy C; Varettoni M; Mangiacavalli S; Zappasodi P; Ventura M; Angeli A; Lazzarino M
    Leukemia; 2004 Sep; 18(9):1555-7. PubMed ID: 15241438
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.